Anya Biopharm (ROCO:7776) EBITDA Margin %: 47.04% (As of Dec. 2025)


ROCO:7776 Anya Biopharm Inc ROCO:7776
12 GF Score
Price NT$31.80
! 4 Warning Signs
View Full Analysis

What is Anya Biopharm EBITDA Margin %?

Anya Biopharm ROCO:7776 12 EBITDA Margin % is 47.04% as of Dec. 2025. GuruFocus rates ROCO:7776 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 939 Biotechnology companies, Anya Biopharm ranks worse than 68.69% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Anya Biopharm's EBITDA for the six months ended in Dec. 2025 was NT$5.80 Mil. Anya Biopharm's Revenue for the six months ended in Dec. 2025 was NT$12.33 Mil. Therefore, Anya Biopharm's EBITDA margin for the quarter that ended in Dec. 2025 was 47.04%.

Anya Biopharm  (ROCO:7776) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Anya Biopharm EBITDA Margin % Related Terms

Anya Biopharm EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Anya Biopharm's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anya Biopharm EBITDA Margin % Chart

Anya Biopharm Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
-1,638.46 -1,154.20 -150.66 -374.16

Anya Biopharm Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial -1,414.75 -4,164.86 -16.19 -1,693.27 47.04

ROCO:7776 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Anya Biopharm's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anya Biopharm EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anya Biopharm's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Anya Biopharm's EBITDA Margin % falls into.


ROCO:7776
12GF Score
Anya Biopharm Inc ROCO:7776
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anya Biopharm EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Anya Biopharm's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-60.88/16.271
=-374.16 %

Anya Biopharm's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=5.801/12.333
=47.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 47.04% mean?
Anya Biopharm (ROCO:7776) has a EBITDA Margin % of 47.04% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anya Biopharm and its competitors. According to the industry distribution chart, Anya Biopharm ranks #645 out of 939 companies in the Biotechnology industry, placing it in the top 68.7%.
Is Anya Biopharm's EBITDA Margin % too high?
Anya Biopharm's current EBITDA Margin % is 47.04%. Based on the distribution chart, Anya Biopharm ranks #645 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anya Biopharm has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Anya Biopharm's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anya Biopharm ranks #645 out of 939 companies for EBITDA Margin %. This places Anya Biopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anya Biopharm and its competitors. Anya Biopharm's current EBITDA Margin % is 47.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anya Biopharm stock overvalued right now?
Anya Biopharm (ROCO:7776) has a current EBITDA Margin % of 47.04%. The current EBITDA Margin % is 47.04%. Anya Biopharm's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Anya Biopharm (ROCO:7776), the current EBITDA Margin % is 47.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anya Biopharm Business Description

Address No. 3-2, Yuanqu Street, 4th Floor, Nangang, Taipei, TWN, 115603
Anya Biopharm Inc is a pharmaceutical company engaged in the Oral Delivery of Peptides. Its patented technology platform Mira/Je is a flexible solution easy to adapt to a large variety of peptides.
12GF Score

Get the complete analysis for ROCO:7776

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.80
Price